MerLion's finafloxacin progresses for severe infections after positive IV results
This article was originally published in Scrip
Early clinical results with an intravenous formulation of MerLion Pharmaceuticals' finafloxacin indicate good potential for the use of the novel fluoroquinolone antibacterial in critical care settings, and further studies in severe, hospital-treated bacterial infections are now getting underway.
You may also be interested in...
While it was not as affected as some other countries, Japan still had the pandemic to deal with and regulators responded while managing to keep up regular product review work, including several world-first approvals. Coronavirus vaccine roll-outs and the first general annual reimbursement price cut are on the cards for this year.
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.